TNFα inhibitors in the treatment of psoriasis and psoriatic arthritis

BioDrugs

Volumn 19, Issue 1, 2005, Pages 47-57

  Tobin, Anne Marie ^a   Kirby, Brian ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; DNA ANTIBODY; ETANERCEPT; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DISTRESS SYNDROME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; INFECTION; INJECTION SITE REACTION; LISTERIA MONOCYTOGENES; MALIGNANT NEOPLASTIC DISEASE; MYCOBACTERIUM INTRACELLULARE AVIUM; NAUSEA; NEUROLOGIC DISEASE; PAIN; PATHOGENESIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SKIN BIOPSY; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15944428248     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200519010-00006     Document Type: Review

References (84)

1. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-204
2. Biondi Oriente C, Scarpa R, Pucino A, et al. Psoriasis and psoriatic arthritis. Acta Dermatol Venereol Suppl 1989; 146: 69-71
3. Burden AD. Identifying a gene for psoriasis on Chromosome 6 (Psor 1). Br J Dermatol 2000 Aug; 143 (2): 238-41
4. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23
5. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis the new therapeutic frontier. Arch Dermatol 2002; 138: 657-63
6. Reish K, Mossner R, Konig IR, et al. Promoter polymorphisms of the genes encoding tumour necrosis factor-alpha and interleukin-1β are associated with different subtypes of psoriasis characterised by early and late onset disease. J Invest Dermatol 2002 Jan; 118 (1): 155-63
7. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51
8. Ackerman L, Harvima IT. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF alpha and their degranulation is associated with expression of ICAM 1 in the epidermis. Arch Dermatol Res 1998; 290: 353-9
9. Gladman DD, Stafford-Brady F, Chang C-H, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809-12
10. Mease PJ. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis 2001; 60: iii37-40
11. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3 (1): 55-78
12. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumour necrosis factor-alpha and other pro-inflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-23
13. Danning CL, Illei GG, Hitchon C, et al. Macrophage-derived cytokine and nuclear factor kB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000; 43: 1244-56
14. Ritchlin C, Haas-smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-52
15. Partsch G, Wagner E, Leeb BF, et al. Upregulation of cytokine receptors sTNF-R75 and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998; 25: 105-10
16. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open label study. Ann Rheum Dis 2000 Jun; 59 (6): 428-33
17. Mease P. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheumatol 2002 Nov-Dec; 20 (6 Suppl. 28): S116-21
18. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2002 Jun 9; 357 (9271): 1842-7
19. Gottlieb A, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumour necrosis factor-a monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003; 48: 68-75
20. Cauza E, Spark M, Cauza K, et al. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumour necrosis factor alpha inhibitor infliximab. Rheumatol Int 2002 Nov; 22 (6): 227-32
21. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumour necrosis factor-alpha, infliximab. J Am Acad Dermatol 2002 Jun; 46 (6): 886-91
22. Antoni C, Dechant C, Hann-Martin Lorenz PD, et al. Open label study of infliximab treatment: clinical and magnetic resonance imaging measurement of reduction of inflammation. Arthritis Rheum 2002 Oct 15; 47 (5): 506-12
23. Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with anti tumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001 Mar; 144 (3): 587-9
24. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumour necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000 May; 42 (Pt 1): 829-30
25. Tan MH, Gordon M, Lebwohl O, et al. Improvement of yoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumour necrosis factor alpha monoclonal antibody. Arch Dermatol 2001 Jul; 137 (7): 930-3
26. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002 Jul; 41 (7): 449-52
27. O'Quinn RP, Miller JL. The effectiveness of tumour necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002 May; 138 (5): 644-8
28. Kirby B, Marsland AM, Carmichael AJ, et al. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001 Jan; 26 (1): 27-9
29. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90
30. Mease PJ. Etanercept, a TNF antagonist for treatment of psoriatic arthritis and psoriasis. Skin Therapy Lett 2003 Jan; 8 (1): 1-4
31. Gottlieb AB, Matheson RT, Lowe NJ, et al. Efficacy of etanercept in patients with psoriasis [abstract]. Ann Dermatol Venereol 2002; 129: 5280
32. Lebwohl M, Gottlieb A, Mease P, et al. Etanercept improves psoriasis activity in patients with psoriatic arthritis: results of a phase III multicentre trial [abstract p56 and poster]. 60th Annual Scientific Meeting of the American Academy of Dermatology; 2002 Feb 22-7; New Orleans
33. Mease PJ, Goffe BS, Metz J, et al. Enbrel (etanercept) in patients with psoriasis and psoriatic arthritis [abstract 2019]. Arthritis Rheum 2000; 43 (9 Suppl.): 403
34. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: one year follow-up [abstract POS-574]. Ann Rheum Dis 2000 Jul; 59 Suppl. 1: 198
35. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years [letter]. Clin Exp Rheumatol 2002; 20 (1): 115
36. Iyer S, Yamanuchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002 Jan; 146 (1): 118-21
37. El Kayam O, Yaron M, Caspi D. From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept [letter]. Ann Rheum Dis 2000 Oct; 59 (10): 839
38. Cuellar ML, Mendez EA, Collins R, et al. Efficacy of etanercept in refractory arthritis (PsA) [abstract 235]. Arthritis Rheum 2000; 43: S106
39. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe resistant psoriatic arthritis. Clin Exp Rheumatol 2000 Nov-Dec; 18 (6): 732-4
40. Kamarashev J, Lor P, Forster A, et al. Generalised pustular psoriasis induced by cyclosporin withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology 2002; 205 (2): 213-6
41. Van den Bosch F, Kruithof E, Baeten D, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002 Mar; 46 (3): 755-65
42. Baeten D, Kruithof E, Van den Dosch F, et al. Immunomodulatory effects of antitumour necrosis factor alpha therapy on synovium in spondylarthropathy; histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001 Jan; 44 (1): 186-95
43. Van den Bosch F, Baeten D, Kruithof E, et al. Treatment of active spondylarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis 2001; 60: iii33-36
44. Wanke LA, Gottlieb AB, Burge DJ, et al. Etanercept improves health related quality of life in patients with psoriatic arthritis [abstract PS31 and poster]. 60th Annual Scientific Meeting of the American Academy of Dermatology; 2002 Feb 22-7; New Orleans
45. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999 Sep; 13 Suppl. 4: 16-22
46. Bazzoni F, Beutler B. The tumour necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-25
47. O'Dell JR. Anticytokine therapy: a new era in the treatment of rheumatoid arthritis? N Engl J Med 1999; 340: 310-2
48. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralising agent. N Engl J Med 2001; 345: 1098-104
49. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumour necrosis factor-alpha neutralising agent [letter]. N Engl J Med 2002; 346: 625-6
50. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infections as a complication of treatment with tumour necrosis factor alpha-neutralising agents. Arthritis Rheum 2003 Feb; 48 (2): 319-24
51. Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, et al. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment [letter]. Am J Gastroenterol 2001; 96: 1665-6
52. Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? [letter]. Am J Gasroenterol 2000; 95: 841-2
53. Kamath BM, Mamul P, Baldassano RN, et al. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 2002; 34: 410-2
54. Gluck T, Linde H-J, Scholmerich J, et al. Anti-tumour necrosis factor therapy and Listeria monocytogenes infection: report of two cases [letter]. Arthritis Rheum 2002; 46: 2255-7
55. Warris A, Bjornklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy [letter]. N Engl J Med 2001; 344: 1099-100
56. Singh SM, Rau N, Cohen LB, et al. Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone. CMAJ 2004 Oct 26; 171 (9): 1063-4
57. Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 76: 653-6
58. Chan ATY, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002; 78: 47-8
59. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease [letter]. Inflamm Bowel Dis 2001; 7: 327
60. Keenan GF, Schaible TF, Boscia JA. Invasive pulmonary aspergillosis associated with infliximab therapy [reply]. N Engl J Med 2001; 344: 1100
61. Cohen RB, Dittirch KA. Anti-TNF therapy and malignancy, a critical review. Can J Gastroenterol 2001 Jun; 15 (6): 376-84
62. Brown SL, Green MH, Gershon SK, et al. Tumour necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drag Administration. Arthritis Rheum 2002 Dec; 46 (12): 3151-8
63. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002; 20 Suppl. 28: S152-157
64. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activity in two multiple sclerosis patients treated with the monoclonal anti tumour necrosis factor antibody cA2. Neurology 1996; 47: 1531-4
65. European Medicines Agency. Summary of product characteristics: Remicade® [online]. Available from URL: http://www.emea.eu.int/humandocs/ PDFs/EPAR/Remicade/190199en4.pdf [Accessed 2003 Apr]
66. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's Disease: a randomised controlled trial. Gastroenterology 2003; 124: 917-24
67. Moreland LW, Cohen SB, Baumgartner SW, et al. Long term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28 (6): 1238-44
68. Fleischman R, Iqbal I, Nandeshwar P, et al. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drag Saf 2002; 25 (3): 173-97
69. Zeltser R, Tanck C, Holyst MM, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumour necrosis factor alpha receptor. Fc fusion protein. Arch Dermatol 2001; 137: 893-9
70. Lovell DJ, Gianninni EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 136: 556-7
71. Skytta E, Pohjanoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000; 18: 533-4
72. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000; 27: 2041-4
73. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999; 131: 634
74. European Medicines Agency. Summary of product characteristics: Enbrel® [online]. Available from URL: http://www.emea.eu.int [Accessed 2003 Apr]
75. Klareskog L, Moreland LM, Bohen SB, et al. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy [abstract 150]. Arthritis Rheum 2001 Sep; 44 Suppl. 9: S77
76. Sabath DF, Holman J, Wallis WJ. Serious infection reports with etanercept (Enbrel) therapy [abstract OPOO00]. Ann Rheum Dis 2002; 61 Suppl. 1: 38
77. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumour necrosis factor receptor: Fc fusion protein. N Engl J Med 1996 Jun 27; 334 (26): 1697-702
78. Philips K, Husni ME, Karlson EW, et al. Experience with etanercept-in an academic medical centre: are infection rates increased? Arthritis Rheum 2002; 47: 17-21
79. Aboulafia DM, Bundow D, Wilske K, et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000 Oct; 75 (10): 1093-8
80. Mohan N, Edwards ET, Cupps TR, et al. Demyelination diagnosed during etanercept (TNF receptor fusion protein) therapy [abstract 970]. Arthritis Rheum 2000; 43: S228
81. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumour necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9
82. Immunex. Enbrel (etanercept) prescribing information [online]. Available from URL: http://www.immunex.com [Accessed 2005 May]
83. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-80
84. Blemuink GS, ter Borg EJ, Ramslaar CG, et al. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001; 40: 1317-9